William Duddy

List of Publications by Year
in descending order

Source: //exaly.com/author-pdf/8253552/publications.pdf

Version: 2024-02-01

49 papers	1,285 citations	341340 20 h-index	372325 34 g-index
50 all docs	50 docs citations	50 times ranked	2266 citing authors

#	Article	IF	Citations
1	Muscular dystrophy in the mdx mouse is a severe myopathy compounded by hypotrophy, hypertrophy and hyperplasia. Skeletal Muscle, 2015, 5, 16.	4.4	111
2	Age-Associated Methylation Suppresses SPRY1 , Leading to a Failure of Re-quiescence and Loss of the Reserve Stem Cell Pool in Elderly Muscle. Cell Reports, 2015, 13, 1172-1182.	6.3	97
3	Molecular and Cellular Mechanisms Affected in ALS. Journal of Personalized Medicine, 2020, 10, 101.	2.6	85
4	Mimicry by asx- and ST-turns of the four main types of Î²-turn in proteins. Protein Science, 2008, 13, 3051-3055.	7.8	66
5	Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy. Molecular Therapy, 2017, 25, 2561-2572.	8.1	63
6	Skeletal muscle characteristics are preserved in hTERT/cdk4 human myogenic cell lines. Skeletal Muscle, 2016, 6, 43.	4.4	60
7	A Systematic Review of Suggested Molecular Strata, Biomarkers and Their Tissue Sources in ALS. Frontiers in Neurology, 2019, 10, 400.	2.5	58
8	Dystrophin deficiency leads to disturbance of LAMP1-vesicle-associated protein secretion. Cellular and Molecular Life Sciences, 2013, 70, 2159-2174.	5.5	55
9	Potential of oligonucleotide-mediated exon-skipping therapy for Duchenne muscular dystrophy. Expert Opinion on Biological Therapy, 2007, 7, 831-842.	3.2	50
10	Activation of Notch Signaling During Ex Vivo Expansion Maintains Donor Muscle Cell Engraftment. Stem Cells, 2012, 30, 2212-2220.	3.6	49
11	Annexin A2 links poor myofiber repair with inflammation and adipogenic replacement of the injured muscle. Human Molecular Genetics, 2017, 26, 1979-1991.	3.0	49
12	In Silico Screening Based on Predictive Algorithms as a Design Tool for Exon Skipping Oligonucleotides in Duchenne Muscular Dystrophy. PLoS ONE, 2015, 10, e0120058.	2.5	47
13	Optimized method for extraction of exosomes from human primary muscle cells. Skeletal Muscle, 2020, 10, 20.	4.4	38
14	A Systematic Review of Genotypeâ€“Phenotype Correlation across Cohorts Having Causal Mutations of Different Genes in ALS. Journal of Personalized Medicine, 2020, 10, 58.	2.6	37
15	Exon skipping for nonsense mutations in Duchenne muscular dystrophy: too many mutations, too few patients?. Expert Opinion on Biological Therapy, 2012, 12, 1141-1152.	3.2	36
16	Exons 45â€“55 Skipping Using Mutation-Tailored Cocktails of Antisense Morpholinos in the DMD Gene. Molecular Therapy, 2019, 27, 2005-2017.	8.1	36
17	Recurring main-chain anion-binding motifs in short polypeptides: nests. Acta Crystallographica Section D: Biological Crystallography, 2004, 60, 1935-1942.	2.4	31
18	Identification of Novel Antisense-Mediated Exon Skipping Targets in DYSF for Therapeutic Treatment of Dysferlinopathy. Molecular Therapy - Nucleic Acids, 2018, 13, 596-604.	5.1	28

#	Article	IF	Citations
19	CellWhere: graphical display of interaction networks organized on subcellular localizations. Nucleic Acids Research, 2015, 43, W571-W575.	14.0	23
20	Exosomes in Ageing and Motor Neurone Disease: Biogenesis, Uptake Mechanisms, Modifications in Disease and Uses in the Development of Biomarkers and Therapeutics. Cells, 2021, 10, 2930.	4.3	23
21	Antisense PMO cocktails effectively skip dystrophin exons 45-55 in myotubes transdifferentiated from DMD patient fibroblasts. PLoS ONE, 2018, 13, e0197084.	2.5	22
22	Muscle cells of sporadic amyotrophic lateral sclerosis patients secrete neurotoxic vesicles. Journal of Cachexia, Sarcopenia and Muscle, 2022, 13, 1385-1402.	7.4	22
23	Changes in Communication between Muscle Stem Cells and their Environment with Aging. Journal of Neuromuscular Diseases, 2015, 2, 205-217.	2.8	19
24	The isolated muscle fibre as a model of disuse atrophy: Characterization using PhAct, a method to quantify f-actin. Experimental Cell Research, 2011, 317, 1979-1993.	2.6	15
25	eSkip-Finder: a machine learning-based web application and database to identify the optimal sequences of antisense oligonucleotides for exon skipping. Nucleic Acids Research, 2021, 49, W193-W198.	14.0	15
26	Atmospheric Oxygen Tension Slows Myoblast Proliferation via Mitochondrial Activation. PLoS ONE, 2012, 7, e43853.	2.5	14
27	What Can Machine Learning Approaches in Genomics Tell Us about the Molecular Basis of Amyotrophic Lateral Sclerosis?. Journal of Personalized Medicine, 2020, 10, 247.	2.6	14
28	Personalized Medicine and Molecular Interaction Networks in Amyotrophic Lateral Sclerosis (ALS): Current Knowledge. Journal of Personalized Medicine, 2018, 8, 44.	2.6	13
29	Arabidopsis Coexpression Tool: a tool for gene coexpression analysis in Arabidopsis thaliana. IScience, 2021, 24, 102848.	4.1	12
30	A Dystrophin Exon-52 Deleted Miniature Pig Model of Duchenne Muscular Dystrophy and Evaluation of Exon Skipping. International Journal of Molecular Sciences, 2021, 22, 13065.	4.2	12
31	RIPK3â€mediated cell death is involved in DUX4â€mediated toxicity in facioscapulohumeral dystrophy. Journal of Cachexia, Sarcopenia and Muscle, 2021, 12, 2079-2090.	7.4	11
32	The Role of Sphingomyelin and Ceramide in Motor Neuron Diseases. Journal of Personalized Medicine, 2022, 12, 1418.	2.6	11
33	Direct Reprogramming of Human DMD Fibroblasts into Myotubes for In Vitro Evaluation of Antisense-Mediated Exon Skipping and Exons 45â€“55 Skipping Accompanied by Rescue of Dystrophin Expression. Methods in Molecular Biology, 2018, 1828, 141-150.	0.0	8
34	Muscle Gene Sets: a versatile methodological aid to functional genomics in the neuromuscular field. Skeletal Muscle, 2019, 9, 10.	4.4	8
35	The Neurotoxicity of Vesicles Secreted by ALS Patient Myotubes Is Specific to Exosome-Like and Not Larger Subtypes. Cells, 2022, 11, 845.	4.3	8
36	The Cellular and Molecular Signature of ALS in Muscle. Journal of Personalized Medicine, 2022, 12, 1868.	2.6	8

#	Article	IF	Citations
37	MyoMiner: explore gene co-expression in normal and pathological muscle. BMC Medical Genomics, 2020, 13, 67.	1.5	7
38	Epidemiology and Survival Trends of Motor Neurone Disease in Northern Ireland from 2015â€2019. European Journal of Neurology, 2021, , .	3.6	7
39	Extracellular Vesicles in Amyotrophic Lateral Sclerosis. Life, 2023, 13, 121.	2.5	4
40	Serum Neurofilaments in Motor Neuron Disease and Their Utility in Differentiating ALS, PMA and PLS. Life, 2023, 13, 1301.	2.5	3
41	Genome-Wide Gene-Set Analysis Approaches in Amyotrophic Lateral Sclerosis. Journal of Personalized Medicine, 2022, 12, 1932.	2.6	2
42	HGCA2.0: An RNA-Seq Based Webtool for Gene Coexpression Analysis in Homo sapiens. Cells, 2023, 12, 388.	4.3	2
43	snpQT: flexible, reproducible, and comprehensive quality control and imputation of genomic data. F1000Research, 2021, 10, 567.	1.6	1
44	snpQT: flexible, reproducible, and comprehensive quality control and imputation of genomic data. F1000Research, 0, 10, 567.	1.6	1
45	Genome-Wide Gene-Set Analysis Identifies Molecular Mechanisms Associated with ALS. International Journal of Molecular Sciences, 2023, 24, 4021.	4.2	1
46	623. Dystrophin Exon 52-Deleted Pigs as a New Animal Model of Duchenne Muscular Dystrophy: Its Characterization and Potential as a Tool for Developing Exon Skipping Therapy. Molecular Therapy, 2016, 24, S247.	8.1	0
47	Understanding Neuromuscular Health and Disease: Advances in Genetics, Omics, and Molecular Function. Journal of Personalized Medicine, 2021, 11, 438.	2.6	0
48	Optimized Molecular Interaction Networks for the Study of Skeletal Muscle. Journal of Neuromuscular Diseases, 2021, 8, 1-17.	2.8	0
49	Isolated Murine Myofibres Undergo Atrophy Ex Vivo Via Diminution of the Myonuclear Domain. FASEB Journal, 2011, 25, 1051.20.	0.5	0